Pancreatic cancer is cancer that forms in the cells of the pancreas. 3d illustration
getty
Pancreatic cancer remains one of the most lethal forms of the disease, largely due to the inaccessibility of its driving protein, which is deeply embedded within cells and beyond the reach of most contemporary treatments. A novel experimental therapy is charting a new course by introducing an antibody directly into the cell to extract the problematic protein. Laboratory and animal studies reveal that this method not only slows cancer progression and reduces tumor size but also largely preserves the healthy version of the protein.
At the core of over 90% of pancreatic cancers lies a specific gene that functions as a toggle for cell proliferation. A minor mutation in this gene causes it to become stuck in the “on” position, leading to uncontrolled cell growth. This same mutation is a significant contributor to numerous colon and lung cancers, establishing it as a prime target in cancer treatment. However, for many years, no medication could effectively target it.
This innovative technique employs small carrier particles to deliver antibodies into the cell. Once inside, the antibody identifies the mutant protein and signals for its removal. This approach combines the targeted precision of an antibody with a delivery system capable of penetrating the cell membrane.
Delivering Antibodies Inside Cells
Antibodies, Y-shaped proteins naturally produced by the body, are designed to bind to specific targets. Over the last thirty years, they have revolutionized the treatment of various cancers, autoimmune disorders, and viral infections.
However, antibodies are typically large and operate outside the cell, targeting proteins on the cell surface or in the bloodstream. Many cancer-causing proteins, such as those encoded by the KRAS gene (Kirsten rat sarcoma viral oncogene homolog), are located deep within the cell, behind an impermeable membrane, making them inaccessible to conventional antibodies.
This new platform addresses this challenge by encapsulating the antibody in a protective particle that traverses the cell membrane and releases its payload once inside. The targeting flexibility inherent in antibodies suggests that this delivery system could be adapted to treat other diseases by substituting different antibodies.
The key challenge is ensuring the antibody discriminates between the mutant and normal versions of the gene. Normal cells require the unmutated KRAS gene for proper function, so a treatment targeting both forms would harm healthy tissue. The antibody in this study is designed to specifically bind to the mutated gene while ignoring the healthy one. This selectivity is vital, as many cancer therapies inadvertently damage healthy tissue along with tumors, causing feared side effects.
What the Experiments Found
In cancer cells possessing the mutant gene, the treatment successfully eliminated the harmful protein. When both mutant and normal cancer cells were analyzed together, only the mutant cells ceased to grow. The healthy cells continued their growth unimpeded.
These findings extended beyond cell cultures. In mice implanted with human pancreatic tumors, repeated injections led to tumor shrinkage, with some tumors becoming nearly undetectable on scans by the study’s conclusion. The mice maintained stable body weight, normal blood test results, and exhibited no organ damage.
How This Differs from Other Drugs
The results come amid growing interest in a new class of drugs aimed at targeting cancers driven by mutations in key signaling genes. One such drug under development, Daraxonrasib, shows promise in trials for pancreatic cancer by attaching to the mutant protein and blocking its growth signal.
This new method differs by not merely controlling the harmful protein but by compelling the cell to eliminate it entirely. This distinction could be significant for gene forms that current drugs struggle to target and for tumors that eventually resist treatment.
A Potential Expansion
The delivery system, when paired with a different antibody, also reduced levels of a protein associated with a brain disorder in preliminary tests. This suggests broader applications. Diseases driven by harmful proteins trapped inside cells, including certain cancers and some dementia forms, might eventually become targets for this approach.
Significant steps remain before this new platform can be used in patient treatments. The current findings are based on lab and animal studies, and human trials will be necessary to confirm these benefits in people. Nonetheless, the path forward is apparent. The future of targeted medicine may involve removing disease-causing proteins rather than simply inhibiting their activity.
